Sandrock Joins Voyager As CEO To Advance New Gene Therapy Technology Into The Clinic
The former Biogen executive will succeed interim CEO Michael Higgins, who will continue as chairman.
You may also be interested in...
The company will prioritize later-stage R&D, including potential accelerated approval for a second anti-amyloid antibody, while replacing its CEO and cutting Aduhelm commercial operations and other costs.
The Swiss giant has gained access to next-generation AAV capsids that could reach cells in the brain, something that has not been possible with technologies used to date.
The coronavirus pandemic may have dominated the news in 2021, but industry’s more bread and butter R&D activities continued. Here, Scrip takes a look at five of the more notable clinical trial misses of the year that got readers clicking.